Amplify Medicines

Amplify Medicines is a clinical-stage precision oncology company focused on developing next-generation small molecule inhibitors for the DNA damage response (DDR) pathway. The company's lead program, AMP-273, is a highly selective and potent ATR inhibitor designed to treat a variety of solid tumors by exploiting synthetic lethal relationships in cancer cells. Amplify Medicines aims to improve upon first-generation DDR inhibitors by optimizing pharmacological properties and clinical combinations. Founded by industry veterans and backed by leading life science investors, the company is headquartered in the Boston biotech hub. Their approach combines deep biological insights with disciplined drug development to address significant unmet needs in oncology.